[FOMX] Foamix Pharmaceuticals Ltd.


Type of security: Stock

Sector: Consumer Durables

Industry: Specialty Chemicals

Market Capitalization: 207.57 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 11.13 Change: 0.13 (1.18%)
Ext. hours: Change: 0 (0%)

chart FOMX

Refresh chart

Strongest Trends Summary For FOMX

FOMX is in the long-term down -62% below S&P in 1 year and down -83% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. Its lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. The company is also developing FMX101 to treat rosacea; and FDX104 to treat chemotherapy-induced rashes, as well as early-stage foam formulations of various drugs for the treatment of dermatological indications, including antibacterial drugs, antifungal drugs, corticosteroids, and immunomodulators. Foamix Pharmaceuticals Ltd. has development and license agreements Bayer AG, Merz Pharmaceuticals, LLC, Actavis plc, Prestium Pharma, Inc. and Arkin Holdings Ltd., and others. It has operations in the United States, Germany, and Israel. The company was founded in 2003 and is headquartered in Rehovot, Israel.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding30.66 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities250 K Cash From Investing Activities-31.18 M Cash From Operating Activities-1.91 M Gross Profit420 K
Net Profit-3.08 M Operating Profit-3.07 M Total Assets49.82 M Total Current Assets42.28 M
Total Current Liabilities3.29 M Total Debt540 K Total Liabilities3.66 M Total Revenue450 K
Technical Data
High 52 week6.3 Low 52 week2.6 Last close2.72 Last change2.26%
RSI24.55 Average true range0.21 Beta0.91 Volume52.12 K
Simple moving average 20 days-11.27% Simple moving average 50 days-23.11% Simple moving average 200 days-36.83%
Performance Data
Performance Week-3.89% Performance Month-20.47% Performance Quart-24.23% Performance Half-31.66%
Performance Year-48.68% Performance Year-to-date-24.23% Volatility daily2.51% Volatility weekly5.61%
Volatility monthly11.5% Volatility yearly39.82% Relative Volume159.06% Average Volume398.21 K
New High0.82% New Low


2019-11-15 20:00:00 | URGENT NEWS: Monteverde & Associates PC Announces an Investigation of FOAMIX PHARMACEUTICALS LTD - FOMX

2019-11-13 16:34:37 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders

2019-11-12 17:09:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

2019-11-12 15:25:00 | FOAMIX PHARMACEUTICALS LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger

2019-11-11 23:00:00 | MERGER INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - KEM, FOMX, WLH

2019-11-11 19:09:00 | FOAMIX ALERT: Bragar Eagel & Squire, P.C. Investigates Proposed Sale of FOMX and Encourages Investors to Contact the Firm

2019-11-11 18:39:21 | Edited Transcript of FOMX earnings conference call or presentation 11-Nov-19 1:30pm GMT

2019-11-11 15:16:44 | Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – FOMX, CISN, PEGI, AXE

2019-11-11 08:00:00 | Menlo, Foamix stocks set for selloffs after all-stock merger deal

2019-11-11 07:30:12 | Foamix FOMX Reports Q3 Loss, Misses Revenue Estimates

2019-11-11 06:00:00 | Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

2019-11-11 06:00:00 | Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

2019-11-10 16:08:20 | The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

2019-11-07 08:00:00 | Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic

2019-11-04 10:30:03 | Will Foamix FOMX Report Negative Earnings Next Week? What You Should Know

2019-11-04 08:01:00 | Foamix Announces Publication of AMZEEQ™ minocycline Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology

2019-11-01 08:00:05 | Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11

2019-10-30 10:33:02 | Will Foamix FOMX Report Negative Q3 Earnings? What You Should Know

2019-10-30 08:45:12 | Have Insiders Been Buying Foamix Pharmaceuticals Ltd. NASDAQ:FOMX Shares?

2019-10-23 16:24:08 | Navigating The Healthcare Industry: Science Fiction Turns to Reality

2019-10-23 08:00:05 | Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103

2019-10-21 08:00:05 | Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam

2019-10-18 16:27:00 | Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers

2019-10-17 11:21:00 | Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

2019-10-14 00:17:21 | 3 Top Biotech Stocks With Major Catalysts in October

2019-10-10 08:00:00 | Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference

2019-09-20 17:14:09 | Foamix Initiates Phase II Study on Acne Combination Foam

2019-09-20 08:00:00 | Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference

2019-09-19 08:00:00 | Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

2019-09-04 08:00:00 | Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037

2019-08-13 20:27:35 | Edited Transcript of FOMX earnings conference call or presentation 8-Aug-19 12:30pm GMT

2019-08-13 09:09:32 | This Latest Target Price On Foamix FOMX Stock Looks Positively Frothy

2019-08-09 10:27:58 | Bank of America Sees Over 350% Upside in Foamix FOMX Stock

2019-08-05 08:02:00 | Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea

2019-07-31 10:36:02 | Will Foamix FOMX Report Negative Earnings Next Week? What You Should Know

2019-07-30 08:00:00 | Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed

2019-07-24 08:00:00 | Foamix Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8

2019-07-11 06:20:16 | Do Directors Own Foamix Pharmaceuticals Ltd. NASDAQ:FOMX Shares?

2019-06-23 16:13:58 | Is Foamix Pharmaceuticals Ltd FOMX A Good Stock To Buy?

2019-06-12 06:29:46 | Barclays Has New Plays for Healthcare Fans

2019-06-04 08:00:00 | Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology

2019-05-15 06:55:16 | Foamix FOMX: A Beaten-Down Biotech Stock That Looks Like a Bargain Now

2019-05-09 15:01:29 | Foamix Pharmaceuticals Ltd. NASDAQ:FOMX: The Best Of Both Worlds

2019-05-09 11:23:41 | Foamix Pharmaceuticals FOMX Q1 2019 Earnings Call Transcript

2019-05-08 19:32:43 | Edited Transcript of FOMX earnings conference call or presentation 8-May-19 12:30pm GMT

2019-05-07 18:05:10 | Foamix FOMX Reports Q1 Loss, Misses Revenue Estimates

2019-05-07 17:03:33 | Foamix: 1Q Earnings Snapshot

2019-05-07 16:21:31 | Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-06 08:00:00 | Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019

2019-04-30 10:32:02 | Will Foamix FOMX Report Negative Earnings Next Week? What You Should Know